Adverse events in second- and third-line treatments for acute and chronic graft-versus-host disease: systematic review
Vladica M Velickovic, Emily McIlwaine, Rongrong Zhang, Tim Spelman
Therapeutic Advances in Hematology | SAGE PUBLICATIONS LTD | Published : 2020
Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is associated with an increased risk of graft-versus-host disease (GvHD), a strong prognostic predictor of early mortality within the first 2 years following allo-HSCT. The objective of this study was to describe the harm outcomes reported among patients receiving second- and third-line treatment as part of the management for GvHD via a systematic literature review. Methods: A total of 34 studies met the systematic review inclusion criteria, reporting adverse events (AEs) across 12 different second- and third-line therapies. Results: A total of 14 studies reported AEs across nine different therapies used in the treatm..View full abstract
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was supported with an unrestricted grant from Mallinckrodt Pharmaceuticals.